Multimodality therapy for locally advanced and limited stage IV breast cancer: The impact of effective non-cross-resistant late-consolidation chemotherapy

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2633-2637

  Blumenschein, George R ^a   Distefano, Alfred ^a   Caderao, Jess ^a   Firstenberg, Barry ^a   Adams, John ^a   Schweichler, Louis H ^a   Drinkard, Lee ^a  

^a Arlington Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS;

EID: 0031431759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Brooks, R. J., Allen, H. J., Salmon, S. E., Jones, S. E., Chase, E., Moon, T. E., and Giordano, G. F. Adjuvant use of Adriamycin and cyclophosphamide in node negative carcinoma of the breast. In: S. E. Salmon and S. E. Jones (eds.). Adjuvant Therapy of Cancer III, pp. 463-470. New York: Grune & Stratton, Inc., 1981.
2. Buzdar, A. U., Hortobagyi, G. N., Singletary, S. E., Holmes, F. A., Theriault, R., Walters, R., Khingra, K., Booser, D., Morris, A., Asmar, L., Wright-Browne, V., Diamandidou, E., Witjaksono, M. A., Strom, E., McNeese, M., and Ames, F. Impact of FAC-adjuvant therapy on mortality of early breast cancer: long-term results of the M. D. Anderson Cancer Center studies. In: S. E. Salmon (ed.). Adjuvant Therapy of Cancer VIII, pp. 93-100. Philadelphia: Lippincott-Raven, 1997.
3. Hortobagyi, G. N., Ames, F. C., Buzdar, A. U., Kau, S-W., McNeese, M. D., Paulus, D., Hug, V., Holmes, F. A., Romsdahl, M. M., Fraschini, G., McBride, C. M., Martin, R. G., and Montague, E. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer (Phila.), 62: 2507-2516, 1988.
4. Hortobagyi, G. N., Ames, F. C., Buzdar, A. U., Kau, S-W., Frye, D., McNeese, M. D., Holmes, F. A., Fraschini, G., Hug, V., and McBride, C. M. Combined modality therapy for locally advanced breast cancer: 14-year results. In: S. E. Salmon (ed.). Adjuvant Therapy of Cancer VI, pp. 254-261. Philadelphia: W. B. Saunders Co., 1990.
5. Koh, E. H., Buzdar, A. U., Ames, F. C., Singletary, S. E., McNeese, M. D., Frye, D., Holmes, F. A., Fraschini, G., Hug, V., Theriault, R. L., Balch, C. M., and Hortobagyi, G. N. Inflammatory carcinoma of the breast: results of a combined-modality approach. M. D. Anderson Cancer Center Experience. Cancer Chemother. Pharmacol., 27; 94-100, 1990.
6. Blumenschein, G., Buzdar, A., Hortobagyi, G., and Yap, H. Adjuvant chemoimmunotherapy of regionally treated stage IV breast cancer patients: a five year follow-up. In: S. E. Salmon and S. E. Jones (eds.). Adjuvant Therapy of Cancer III, pp. 427-434. New York: Grune & Stratton, Inc., 1981.
7. Swenerton, K., Legha, S. S., Smith, T., Hortobagyi, G. N., Geham, E., Yap, H. Y., Gutterman, J. U., and Blumenschein, G. R. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res., 39: 1552-1562, 1979.
8. Feldman, L., Hortobagyi, G., Buzdar, A., and Blumenschein, G. Pathologic complete remission (CR) in patients (PTS) with inflammatory breast cancer (IBC) and locally advanced breast cancer (LABC). Proc. Am. Assoc. Cancer Res., 25: 197, 1984.
9. Feldman, L. D., Hortobagyi, G. N., Buzdar, A. U., Ames, F. C., and Blumenschein, G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res., 46: 2578-2581, 1986.
10. Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., and Harris, J. R. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N. Engl. J. Med., 334: 1356-1361, 1996.
11. Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., Kardinal, C. G., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol., 8: 1483-1496, 1990.
12. Hortobagyi, G. N., Singletary, S. E., and McNeese, M. D. Treatment of locally advanced and inflammatory breast cancer. In: J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds.). Diseases of the Breast, pp. 585-599. Philadelphia: Lippincott-Raven, 1996.
13. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J. Clin. Oncol., 15: 1384-1394, 1997.
14. Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet, i: 1256-1260, 1984.
15. Boccardo, F., Rubagotti, A., Bruzzi, P., Cappellini, M., Isola, G., Nenci, I., Piffanelli, A., Scanni, A., Sismondi, P., Santi, L., et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J. Clin. Oncol., 8: 1310-1320, 1990.
16. Rivkin, S. E., Green, S., Metch, B., Cruz, A. B., Abeloff, M. D., Jewell, W. R., Costanzi, J. J., Farrar, W. B., Minton, J. P., and Osborne, C. K. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J. Clin. Oncol., 12: 2078-2085, 1994.
17. Fisher, B., Redmond, C., Legault-Poisson, S., Dimitrov, N. V., Brown, A. M., Wickerham, D. L., Wolmark, N., Margolese, R. G., Bowman, D., Glass, A. G., et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol., 8: 1005-1018, 1990.
18. Fisher, B., Redmond, C., Brown, A., et al. Adjuvant chemotherapy with and without tamoxifen: five-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J. Clin. Oncol., 4: 459-471, 1986.
19. Osborne, C. K. Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In: V. C. Jordan (ed.). Long Term Tamoxifen for Breast Cancer, pp. 181-198. Madison, WI: University of Wisconsin, 1994.
20. Pronzato, P., Sertoli, M. R., Amoroso, D., et al. Concurrent versus sequential adjuvant chemo-hormonotherapy for stage II breast cancer. In: S. E. Salmon (ed.). Adjuvant Therapy of Cancer VI, pp. 297-304. Philadelphia: W. B. Saunders, 1990.
21. Peters, W. P., Ross, M., Vredenburgh, J. J., Meisenberg, B., Marks, L. B., Winer, E., Kurtzberg, J., Bast, R. C., Jr., Jones, R., Shpall, E., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol., 11: 1132-1143, 1993.
22. Blumenschein, G. R., DiStefano, A., and Gomez-Yeyille, J. E. Response to initial combination chemotherapy as a predictor of response to CMF cisplatinum (McCFUD) combination therapy for metastatic breast cancer. Proc. Am. Assoc. Cancer Res., 28: 199, 1987.
23. Kaplan, E. R., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457, 1958.
24. Blumenschein, G. R., DiStefano, A., Firstenberg, B. A., Kelly, J. P., and Gomez-Yeyille, J. E. Response of measurable metastatic breast cancer to combination cyclophosphamide, doxorubicin, VP16 (CaVe). Proc. Am. Assoc. Cancer Res., 29: 196, 1988.
25. Blumenschein, G. R., Cardenas, J. O., Freireich, E. J., and Gottlieb, J. A. FAC chemotherapy for breast cancer. Proc. Am. Soc. Oncol., 15: 193, 1974.
26. Peters, W. P., Dansey, R., Klein, J., and Berry, D. High-dose chemotherapy for high-risk primary breast cancer. In: S. E. Salmon (ed.). Adjuvant Therapy of Cancer VIII, pp 117-122. Philadelphia: Lippincott-Raven, 1997.
27. Goldie, J. H., and Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat. Rep., 63: 1727-1733, 1979.
28. Blumenschein, G. R. Tumor burden killed by Adriamycin combination therapy in metastatic breast cancer. In: S. E. Jones and S. E. Salmon (eds.). Adjuvant Therapy of Breast Cancer II, pp. 71-78. New York: Grune & Stratton Inc., 1979.
29. Withers, H. R. Biologic basis of radiation therapy. In: C. A. Perez and L. W. Brady (eds.). Principles and Practice of Radiation Oncology. 1987.